These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21757054)

  • 1. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy.
    Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Palombo-Kinne E; Kuhl H
    Contraception; 2011 Aug; 84(2):133-43. PubMed ID: 21757054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters.
    Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Kuhl H
    Contraception; 2008 Nov; 78(5):384-91. PubMed ID: 18929735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
    Ahrendt HJ; Makalová D; Parke S; Mellinger U; Mansour D
    Contraception; 2009 Nov; 80(5):436-44. PubMed ID: 19835717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use.
    Sänger N; Stahlberg S; Manthey T; Mittmann K; Mellinger U; Lange E; Kuhl H; Wiegratz I
    Contraception; 2008 Jun; 77(6):420-5. PubMed ID: 18477491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
    Jensen JT; Garie SG; Trummer D; Elliesen J
    Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in Poland.
    Golbs S; Domhardt R; Radowicky S; Kałuzny Z; Wisser KH; Zimmermann T
    Methods Find Exp Clin Pharmacol; 2002 Nov; 24(9):585-92. PubMed ID: 12616705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
    Portman DJ; Kaunitz AM; Howard B; Weiss H; Hsieh J; Ricciotti N
    Contraception; 2014 Apr; 89(4):299-306. PubMed ID: 24576794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A look at the long-term safety of an extended-regimen OC.
    Davis MG; Reape KZ; Hait H
    J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
    Palombo-Kinne E; Schellschmidt I; Schumacher U; Gräser T
    Contraception; 2009 Apr; 79(4):282-9. PubMed ID: 19272497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.
    Kaunitz AM; Portman DJ; Hait H; Reape KZ
    Contraception; 2009 May; 79(5):350-5. PubMed ID: 19341846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days.
    Foidart JM; Sulak PJ; Schellschmidt I; Zimmermann D;
    Contraception; 2006 Jan; 73(1):34-40. PubMed ID: 16371292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.
    Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I
    Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial.
    Palacios S; Wildt L; Parke S; Machlitt A; Römer T; Bitzer J
    Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):57-62. PubMed ID: 19969409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial.
    Stewart FH; Kaunitz AM; Laguardia KD; Karvois DL; Fisher AC; Friedman AJ
    Obstet Gynecol; 2005 Jun; 105(6):1389-96. PubMed ID: 15932834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies.
    Endrikat J; Parke S; Trummer D; Schmidt W; Duijkers I; Klipping C
    Contraception; 2008 Sep; 78(3):218-25. PubMed ID: 18692612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use.
    Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Palombo-Kinne E; Mellinger U; Lange E; Kuhl H
    Contraception; 2010 Jan; 81(1):57-61. PubMed ID: 20004274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC; Filho CI; Faggion D; Baracat EC
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
    Brucker C; Hedon B; The HS; Höschen K; Binder N; Christoph A
    Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined hormonal contraception in cycles artificially extended].
    Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
    Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L; Kunz M; Marr J
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.